Compare Ford Motor Company (F) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs IDEXX Laboratories, Inc. — how do they compare? Ford Motor Company trades at $12.28 (market cap $48.85B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B). The key difference: Ford Motor Company is the larger of the two by market cap, and Ford Motor Company pays a 4.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| F | IDXX | |
|---|---|---|
Market Cap | $48.85B | $40.43B |
Volume | 57,748,965 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $766.68 |
52-Week Low | $11.21 | $504.70 |
Typical Hold Time | 104 Days | 46 Days |
Enterprise Value | $180.81B | $41.32B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% on the day, amid a challenging quarter with a 6.6% sales decline reported for Q3 2026 (Reuters, 2026-10-02). The stock shows a bearish technical signal, with moving averages indicating a downtrend. Fundamentally, the company reported a net loss of $8.18 billion for 2025, with negative profit margins and ROE, though operating cash flow remains strong at $21.28 billion. Recent news highlights supplier disruptions affecting F-150 production and a strategic shift toward hybrids.
The outlook for Ford is mixed, with analyst consensus leaning toward a 'Hold' (48.93% of ratings) and a price target of $15.90 suggesting potential upside. Key opportunities include the growing hybrid segment and strong commercial division, while risks involve ongoing sales volatility, high debt levels, and competitive pressures from Asian automakers. Investors should weigh the company's cash flow strength against profitability challenges and market share losses.
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
